$3.32 -0.15 (%) Vivus Inc - NASDAQ

Oct. 22, 2014 | 04:00 PM

Partner Headlines

  1. Bank Of America Q3 Small & Mid-Cap Biotech Preview

    Benzinga | Oct. 20, 2014 | 16:58PM EST
  2. Endo Buyout Of Auxilium Joins Two Changing Firms

    IBD | Oct. 9, 2014 | 19:00PM EST
  3. Vivus, Inc. Opens Sharply Higher On ED Drug Marketing Approval

    Benzinga | Sep. 18, 2014 | 09:55AM EST
  4. Morning Market Movers

    Benzinga | Sep. 18, 2014 | 09:46AM EST
  5. Benzinga's Top #PreMarket Gainers

    Benzinga | Sep. 18, 2014 | 08:05AM EST
  6. US Stock Futures Up Ahead Of Jobless Claims, Housing Starts Data

    Benzinga | Sep. 18, 2014 | 07:10AM EST
  7. FDA delays Orexigen drug

    IBD | Jun. 11, 2014 | 18:57PM EST
  8. Orexigen Obesity Drug Decision Delayed By FDA

    IBD | Jun. 11, 2014 | 11:55AM EST
  9. Orexigen Shares Plummet Following FDA Decision; Competition Gets A Bump

    Benzinga | Jun. 11, 2014 | 11:24AM EST
  10. Is Vivus About To Get Squeezed?

    Benzinga | Jun. 9, 2014 | 14:54PM EST
  11. Benzinga's Top #PreMarket Gainers

    Benzinga | May. 6, 2014 | 08:06AM EST
  12. Shares of Vivus Fall +10% Following Piper Jaffray's Downgrade

    Benzinga | Apr. 3, 2014 | 13:03PM EST
  13. Mid-Day Market Update: US Stocks Fall; Google Shares Rise After Stock Split

    Benzinga | Apr. 3, 2014 | 12:41PM EST
  14. Mid-Morning Market Update: Markets Mostly Flat; Greenbrier Results Beat Estimates

    Benzinga | Apr. 3, 2014 | 10:43AM EST
  15. Morning Market Losers

    Benzinga | Apr. 3, 2014 | 09:49AM EST
  16. Benzinga's Top #PreMarket Losers

    Benzinga | Apr. 3, 2014 | 08:29AM EST
  17. Benzinga's Top Downgrades

    Benzinga | Apr. 3, 2014 | 07:47AM EST
  18. Biotech Auxilium Boosts Position In Men's Health Care

    IBD | Apr. 1, 2014 | 17:31PM EST
  19. Weekly Three-Year Low Highlight: VVUS, RALY, WILN, COVS

    GuruFocus | Mar. 25, 2014 | 11:50AM EST
  20. Vivus Announces Review Article Summarizing Cardiovascular Benefit-Risk Profile of Qsymia

    Benzinga | Mar. 25, 2014 | 07:50AM EST
  21. Auxilium Q4 Beats Estimates, But Guidance Cautious

    IBD | Feb. 28, 2014 | 10:42AM EST
  22. Mid-Afternoon Market Update: Markets Turn Red as Tesla Continues to Rip Higher

    Benzinga | Feb. 25, 2014 | 15:51PM EST
  23. Mid-Day Market Update: US Stocks Mostly Flat; Office Depot Shares Decline On Q4 Results

    Benzinga | Feb. 25, 2014 | 13:07PM EST
  24. Mid-Morning Market Update: Markets Fall; Home Depot Profit Beats Estimates

    Benzinga | Feb. 25, 2014 | 11:44AM EST
  25. UPDATE: Vivus Down Nearly 12% After JP Morgan Downgrade on Lackluster Qsymia News

    Benzinga | Feb. 25, 2014 | 11:30AM EST
  26. Stocks Hitting 52-Week Lows

    Benzinga | Feb. 25, 2014 | 10:21AM EST
  27. Morning Movers for Feb. 25, 2014: IMUC, MSO, ZU, CARA, VSI, TSLA, XOMA, BCRX Moving Higher, RP, ODP, VVUS, AINV, MGIC, ALSN Lower

    Benzinga | Feb. 25, 2014 | 09:41AM EST
  28. Benzinga's Top #PreMarket Losers

    Benzinga | Feb. 25, 2014 | 08:14AM EST
  29. UPDATE: Bank of America Downgrades Vivus as Partnering Prospects Weaken

    Benzinga | Feb. 25, 2014 | 08:12AM EST
  30. US Stock Futures Slip Ahead Of Economic Data

    Benzinga | Feb. 25, 2014 | 07:22AM EST
  31. Benzinga's Top #PreMarket Gainers

    Benzinga | Jan. 14, 2014 | 08:09AM EST
  32. The Top Five Drug Launches Of 2013

    IBD | Dec. 31, 2013 | 13:42PM EST
  33. New ED Drug: Analysis of Vivus’s Prospects

    YCharts | Dec. 23, 2013 | 14:09PM EST
  34. VIVUS Announces License and Commercialization Agreement With Sanofi for Avanafil in Africa, Middle East, Turkey and CIS/Russia

    Benzinga | Dec. 12, 2013 | 07:01AM EST
  35. VIVUS Awarded Two US Patents for Qsymia; Patent Coverage for Qsymia Extended to 2029

    Benzinga | Nov. 13, 2013 | 07:03AM EST
  36. Stocks Hitting 52-Week Lows

    Benzinga | Nov. 6, 2013 | 10:20AM EST
  37. UPDATE: Bank of America Downgrades Vivus on Weaker Partnering Prospects

    Benzinga | Nov. 6, 2013 | 09:09AM EST
  38. Benzinga's Top Downgrades

    Benzinga | Nov. 6, 2013 | 07:57AM EST
  39. US Stock Futures Up Ahead Of Time Warner Earnings

    Benzinga | Nov. 6, 2013 | 07:08AM EST
  40. How Arena’s “$3 Billion” Belviq Withered

    YCharts | Nov. 1, 2013 | 12:38PM EST
  41. UPDATE: Piper Jaffray Downgrades VIVUS Following Management Meetings

    Benzinga | Oct. 16, 2013 | 12:52PM EST
  42. Benzinga's Top Pre-Market Losers

    Benzinga | Oct. 16, 2013 | 08:19AM EST
  43. Vivus, Auxilium up on deal

    IBD | Oct. 11, 2013 | 18:38PM EST
  44. Vivus, Auxilium Gain On Impotence Drug Deal

    IBD | Oct. 11, 2013 | 11:08AM EST
  45. Clinton Group Sends Letter to VIVUS CEO, Says Co. Should Do More to Give Info on Strength of 2020 Patents

    Benzinga | Oct. 11, 2013 | 08:31AM EST
  46. Auxilium Pharmaceuticals Announces License Agreement with Vivus for Marketing Rights to STENDRA In US, Canada

    Benzinga | Oct. 11, 2013 | 07:07AM EST
  47. Benzinga's Top Pre-Market Gainers

    Benzinga | Oct. 9, 2013 | 08:10AM EST
  48. Obesity drugs up on report

    IBD | Oct. 3, 2013 | 18:50PM EST
  49. Vivus Weighs In As a Leader for Diet Pills, Cowen Upgrades and Raises PT

    Benzinga | Oct. 3, 2013 | 16:42PM EST
  50. Obesity Drug Stocks Jump As Cowen Gets Bullish

    IBD | Oct. 3, 2013 | 13:20PM EST
Trading Center